Riskpilot← Back to searchSign inGet full accessINJECT ApS
APSActiveCVR 33867581Vejlegade 7, 1. thBusiness and other management consultancy activities · NACE 7020Est. 2011— employees
Revenue 2025
DKK 0
EBITDA margin
—
Equity ratio
—
Financial strength
Net profit 2025
DKK 0
| Revenue | DKK 0 | — |
| EBITDA | DKK 0 | — |
| Net profit | DKK 0 | — |
| Total assets | DKK 0 | — |
| Equity | DKK 0 | — |
| Employees | — | — |
Legal name
INJECT ApS
CVR number
33867581
Legal form
Anpartsselskab
NACE code
7020 · Business and other management consultancy activities
Founded
3. august 2011
Share capital
DKK 85.263
Employees
—
VAT registered
Yes
Audit selected
No
Last report
2025-08-31
Financial year
January – December
Signatory rights
Selskabet tegnes af én direktør.
Company purpose
Selskabets formål er at drive virksomhed med udvikling, markedsføring og distribution af medicinske redskaber og dermed efter bestyrelsens opfattelse beslægtet virksomhed.
Address
Vejlegade 7, 1. th
Phone
+4561143305
Email
Tina.hetting@live.dk
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | -14 | -11 | -59 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBITDA | -27 | -14 | -11 | -59 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | -27 | -14 | -11 | -59 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net financials | 0 | 0 | -0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | -27 | -14 | -11 | -59 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Tax | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| Net profit | -27 | -14 | -11 | -59 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 2.814 | 2.862 | 3.062 | 3.014 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity | 554 | 588 | 577 | 519 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 2.250 | 2.273 | 2.484 | 2.495 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total debt | 2.250 | 2.273 | 2.484 | 2.495 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EBITDA margin
0.0%
This company
15.8%
Market median
-100% vs market
20122025
Equity ratio
0.0%
This company
38.2%
Market median
-100% vs market
20122025
Return on equity
0.0%
This company
18.4%
Market median
-100% vs market
20122025
Net profit margin
0.0%
This company
8.1%
Market median
-100% vs market
20122025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20122025
Debt / equity
-1.00×
This company
0.62×
Market median
+261% vs market
20122025
- Annual report 2025Filed via CVR / Virk · Period 2024-09-01 – 2025-08-31
- Annual report 2024Filed via CVR / Virk · Period 2023-09-01 – 2024-08-31
- Annual report 2023Filed via CVR / Virk · Period 2022-09-01 – 2023-08-31
- Annual report 2022Filed via CVR / Virk · Period 2021-09-01 – 2022-08-31
- Annual report 2021Filed via CVR / Virk · Period 2020-09-01 – 2021-08-31
- Annual report 2020Filed via CVR / Virk · Period 2019-10-01 – 2020-08-31
- Annual report 2019Filed via CVR / Virk · Period 2018-10-01 – 2019-09-30
- Annual report 2018Filed via CVR / Virk · Period 2017-10-01 – 2018-09-30
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-09-30
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via CVR / Virk · Period 2011-08-03 – 2012-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
HB Founder | Founder | 2011 | — | — |
FH Management | Management | 2024 | — | — |
LW Management | Management | 2013 | — | — |
MH Management | Management | 2017 | — | — |
JH Chief Executive Officer | Chief Executive Officer | 2013 | — | — |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Tina Hetting Holding I ApS | Company | 33.3% | 33.3% | 2020 |
MAFO ApS | Company | 20.0% | 20.0% | 2011 |
| Individual | 20.0% | 20.0% | 2011 | |
TINA HETTING HOLDING ApS | Company | 33.3% | 33.3% | 2019 |
ACC AF 2010 A/S | Company | 5.0% | 5.0% | 2012 |
ØRESUNDSHØJ MEDICO ApS | Company | 50.0% | 50.0% | 2011 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of INJECT ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Helle Birgitte Adamsen | Founder | 0 companies |
| Felix Hetting | Management | 0 companies |
| Lars Wexøe | Management | 0 companies |
| Mikael Hans Andranik Hetting | Management | 0 companies |
| John Holger Adamsen | Chief Executive Officer | 0 companies |